RVXOT/narmac - I very clearly remember the comments on the board around 2017 completion and also the comments around the fact that those who thought that would happen were dreaming or something like that. In Nov 2015 when the first patient was recruited there were only 2 or 3 clinics register for the trial out of some 200 or more that were expected to participate. Many of the clinics would get their training beginning in Feb 2016 with the bulk of the clinics training in April 2016. BDAZ constantly posted updates with the number of recruits up to each date that numbers were given. It was always stated that the patients needed 104 weeks of dosing from time of recruitment except for the last patients recruited which required a minimum of 52 weeks on dose. The presentation at the 2015 AGM outlined a time frame for recruitment and completion of the trial with end of dosing by end of 2018. This was discussed on this board at that time. 

My point here; The end of 2017 was never in the cards for end of dosing and end of recruitment by that time was still iffy. For the trial to be finished dosing by the end of 2017 there would have to have been 2400 patients recruited within 6 weeks of the dosing of the first patient. Logic said that would never happen.

As for the cost of the trial, yes there were some challenges, unfortunately some that were not caused by RVX but had to be worked around. It was what it was and is what it is. When your in a business that only spends money you accept that challenge right up front. That has also been discussed a number of times on this board. That's not an excuse for less than stellar planning, just a reality.

tada